Azurity Pharmaceuticals, Inc. (Azurity) announced the closing of its acquisition of Slayback Pharma LLC (Slayback) from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity. The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The…